Posting of Annual Report and Notice of AGM

RNS Number : 6775M

Destiny Pharma PLC

12 May 2020

 

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Posting of Annual Report and Accounts, and Notice of AGM

Brighton, United Kingdom - 12 May 2020 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance (AMR), announces that the following documents are now available on the Company's website at   www.destinypharma.com

· Annual Report and Accounts of the Company for the year ended 31 December 2019

· Notice of the 2020 Annual General Meeting ("AGM) which is to be held at 10.30am on 10 June, 2020

Printed copies of both documents will be posted to shareholders today.

To comply with the UK Government's Stay at Home measures, shareholders will not be allowed to attend the meeting in person. Shareholders are strongly encouraged to therefore submit their votes, in respect of all matters of business, via proxy as early as possible. They should appoint the Chairman of the meeting as their proxy. If the situation changes then shareholders will be notified via the Company's website at www.destinypharma.com   and via RNS announcement.

For further information, please contact:

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

[e-mail]  

[phone]

FTI Consulting

Simon Conway / Victoria Foster Mitchell

[e-mail]  

[phone]

finnCap Ltd   (Joint Broker)

Geoff Nash / Kate Bannatyne, Corporate Finance

Alice Lane, Corporate Broking

[phone]

WG Partners   (Joint Broker)

Nigel Barnes / Claes Spång / Nigel Birks

[phone]

About Destiny Pharma

Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel, cost effective medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as "superbugs". Tackling anti-microbial resistance has become a global imperative recognised by the World Health Organisation (WHO) and the United Nations, as well as the G7 and the G20 countries. For further information, please visit   https://www.destinypharma.com  

 

END

 

 

MSCATMITMTBBBTM